Statistiques de base
| LEI | 5493000L48S51ZYDK260 |
| CIK | 1630113 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Biotricity, Inc.
SEC Filings (Chronological Order)
Cette page fournit une liste complète et chronologique des documents déposés auprès de la SEC, à l'exclusion des documents relatifs à la participation que nous fournissons ailleurs.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number: 001-40761 BIOTRICITY INC. (Exact n |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No.1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40761 BIOTRICITY INC. (Exact name of registrant as |
|
| July 15, 2025 |
Description of Registrant’s Securities Exhibit 4.13 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Biotricity, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, which is the Company’s common stock, $0.001 par value per share. Description of Common Stock The authorized capital stock of the C |
|
| July 15, 2025 |
Exhibit 19 BIOTRICITY, INC. STATEMENT OF COMPANY POLICY REGARDING CONFIDENTIALITY AND SECURITIES TRADES BY COMPANY PERSONNEL 1. CONFIDENTIALITY OF INSIDE INFORMATION 1.1 Directors, officers, employees and consultants (“Company Personnel”) of Biotricity, Inc. (the “Company”), who come into possession of material non-public information concerning the Company must safeguard the information and not in |
|
| July 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40761 BIOTRICITY INC. (Exact name of registrant as specified in its ch |
|
| July 15, 2025 |
Exhibit 97 BIOTRICITY INC. CLAWBACK POLICY Introduction The Board of Directors (the “Board”) of Biotricity Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR Fo |
|
| February 24, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 20, 2025 BIOTRICITY INC. |
|
| February 24, 2025 |
Exhibit 99.1 Biotricity Delivers Record Margins, Record Revenues, and Record Cashflows with 21.7% Year-Over-Year Sales Growth for its Third Quarter of Fiscal 2025 ● Company reports Q3-FY25 revenue grew by 21.7% YOY to $3.6 million ● Management continues to drive revenues and efficiencies ● Company achieved positive cash flow on current operating basis, before paying interest, dividends and amortiz |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number: 001-40761 |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number: 001-40761 BIOTRICITY INC. (Exa |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR |
|
| November 20, 2024 |
Exhibit 99.1 Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025 ● Company achieved positive cash flow in September on a current operating basis, before paying interest, dividends and amortization; management expects to continue to see cash flows improve ● Company reports Q2-FY25 revenue grew by 13% YOY to $3.3 million ● Gro |
|
| November 20, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2024 BIOTRICITY INC. |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number: 000-56074 BIOTRICITY INC. (Ex |
|
| November 14, 2024 |
BTCY / Biotricity, Inc. / Ionic Ventures, LLC - SC 13G/A Passive Investment SC 13G/A 1 g084562sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biotricity Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09074H203 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number: 001-40761 BIOTRICITY INC. (Exact n |
|
| August 16, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 15, 2024 BIOTRICITY INC. |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For |
|
| August 8, 2024 |
BTCY / Biotricity, Inc. / Ionic Ventures, LLC - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Biotricity Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09074H203 (CUSIP Number) July 8, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| August 7, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 1, 2024 BIOTRICITY INC. |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| August 1, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 26, 2024 BIOTRICITY INC. |
|
| July 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| July 16, 2024 |
Side letter, dated July 16, 2024 Exhibit 10.1 |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 16, 2024 BIOTRICITY INC. |
|
| July 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 12, 2024 BIOTRICITY INC. |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-56074 BIOTRICITY INC. (Exact name of registrant as s |
|
| June 27, 2024 |
Exhibit 19 BIOTRICITY, INC. STATEMENT OF COMPANY POLICY REGARDING CONFIDENTIALITY AND SECURITIES TRADES BY COMPANY PERSONNEL 1. CONFIDENTIALITY OF INSIDE INFORMATION 1.1 Directors, officers, employees and consultants (“Company Personnel”) of Biotricity, Inc. (the “Company”), who come into possession of material non-public information concerning the Company must safeguard the information and not in |
|
| June 27, 2024 |
Exhibit 97 BIOTRICITY INC. CLAWBACK POLICY Introduction The Board of Directors (the “Board”) of Biotricity Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-56074 BIOTRICITY INC. (Exact name of registrant as specified in its ch |
|
| June 27, 2024 |
Description of Registrant’s Securities Exhibit 4.13 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Biotricity, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, which is the Company’s common stock, $0.001 par value per share. Description of Common Stock The authorized capital stock of the C |
|
| June 24, 2024 |
Form of Registration Rights Agreement Exhibit 10.2 IN WITNESS WHEREOF, the parties have caused this Registration Rights Agreement to be duly executed as of day and year first above written. THE COMPANY: BIOTRICITY INC. By: Name: Waqaas Al-Siddiq Title: CEO BUYER: IONIC VENTURES, LLC By: Name: Title: |
|
| June 24, 2024 |
Exhibit 10.3 VOTING AGREEMENT VOTING AGREEMENT, dated as of June 21, 2024 (this “Agreement”), by and among Biotricity Inc., a Nevada corporation, (the “Company”), Ionic Ventures, LLC (the “Investor”), and the stockholders whose names appear on the signature pages hereto (each, a “Stockholder” and collectively, the “Stockholders”). WHEREAS, the Company and the Investor have entered into a Securitie |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2024 BIOTRICITY INC. |
|
| June 24, 2024 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 21, 2024, is by and among Biotricity Inc., a Nevada corporation with offices located at 203 Redwood Parkway, Suite 600, Redwood City, CA 94065 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buy |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| June 7, 2024 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 4, 2024 BIOTRICITY INC. |
|
| May 28, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 28, 2024 BIOTRICITY INC. |
|
| May 28, 2024 |
Biotricity Inc. Up to $2,684,644 Common Stock PROSPECTUS SUPPLEMENT (To Prospectus dated May 15, 2024) Filed Pursuant to 424(b)(3) File No. |
|
| May 28, 2024 |
Exhibit 10.1 May 28, 2024 Biotricity Inc. 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648 Attention: Waqaas Al-Siddiq, Chief Executive Officer Dear Mr. Al-Siddiq: Reference is made to the At The Market Offering Agreement, dated as of March 22, 2022 (the “ATM Agreement”), between Biotricity Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”). This letter (the “Amendment”) constit |
|
| May 21, 2024 |
Side letter, dated May 15, 2024 Exhibit 10.1 Biotricity Inc. Amended Side Letter May 15, 2024 May 15, 2024 Ionic Ventures, LLC 3053 Fillmore St., Suite 256 San Francisco, CA 94123 Re: Modification of the Securities Purchase Agreement by Amended Letter Agreement Dear Sirs: Reference is made to that certain (a) (i) Securities Purchase Agreement (as modified from time to time, the “Securities Purchase Agreement”), dated as of March |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2024 BIOTRICITY INC. |
|
| May 16, 2024 |
2,095,238 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Under the Securities Act of 1933, as amended Registration No. |
|
| May 15, 2024 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Biotricity, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee N |
|
| May 15, 2024 |
As filed with the Securities and Exchange Commission on May 15, 2024 As filed with the Securities and Exchange Commission on May 15, 2024 Registration Statement No. |
|
| May 15, 2024 |
Biotricity Inc. 203 Redwood Parkway, Suite 600 Redwood City, CA 94065 Biotricity Inc. 203 Redwood Parkway, Suite 600 Redwood City, CA 94065 May 15, 2024 EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Biotricity Inc. Registration Statement on Form S-3 File No. 333-279284 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, B |
|
| May 14, 2024 |
Biotricity Inc. 203 Redwood Parkway, Suite 600 Redwood City, CA 94065 Biotricity Inc. 203 Redwood Parkway, Suite 600 Redwood City, CA 94065 May 14, 2024 EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Biotricity Inc. Registration Statement on Form S-3 File No. 333-279226 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, B |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration Statement No. |
|
| May 9, 2024 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Biotricity, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee N |
|
| May 8, 2024 |
As filed with the Securities and Exchange Commission on May 8, 2024 As filed with the Securities and Exchange Commission on May 8, 2024 Registration Statement No. |
|
| May 8, 2024 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) BIOTRICITy INC. (Exact name of Registrant as specified in its charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Fees |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 30, 2024 BIOTRICITY INC. |
|
| May 3, 2024 |
Exhibit 10.2 EXECUTION COPY REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 25, 2024 (the “Signing Date”), by and between Biotricity Inc., a Nevada corporation (the “Company”), and the undersigned signatory hereto (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respect |
|
| April 25, 2024 |
April 25, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 23, 2024 BIOTRICITY INC. |
|
| April 23, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-255544 Amendment No. 1 dated April 22, 2024 to Prospectus Supplement dated September 19, 2023 (To Prospectus dated May 4, 2021) EXPLANATORY NOTE This Amendment No. 1 to prospectus supplement dated September 19, 2023 is being filed to reduce the aggregate amount of common stock that we are offering to correct an error in calculation. No other ch |
|
| April 3, 2024 |
Exhibit 3.1 AMENDED CERTIFICATE OF DESIGNATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK OF BIOTRICITY INC. I, Waqaas Al-Siddiq, hereby certify that I am the Chief Executive Officer of Biotricity Inc. (the “Company”), a corporation organized and existing under the Nevada Revised Statutes (the “NRS”), and further do hereby certify: That pursuant to the authority expressly conferred upon the Board of |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 1, 2024 BIOTRICITY INC. |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 25, 2024 BIOTRICITY INC. |
|
| March 26, 2024 |
Exhibit 10.3 VOTING AGREEMENT VOTING AGREEMENT, dated as of March 25, 2024 (this “Agreement”), by and among Biotricity Inc., a Nevada corporation, (the “Company”), [ ] (the “Investor”), and the stockholders whose names appear on the signature pages hereto (each, a “Stockholder” and collectively, the “Stockholders”). WHEREAS, the Company and the Investor have entered into a Securities Purchase Agre |
|
| March 26, 2024 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 25, 2024 (the “Signing Date”), by and between Biotricity Inc., a Nevada corporation (the “Company”), and the undersigned signatory hereto (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings se |
|
| March 26, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 25, 2024, is by and among Biotricity Inc., a Nevada corporation with offices located at 203 Redwood Parkway, Suite 600, Redwood City, CA 94065 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Bu |
|
| February 28, 2024 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Biotricity Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price(1)(2) Fee Rat |
|
| February 28, 2024 |
As filed with the Securities and Exchange Commission on February 27, 2024 As filed with the Securities and Exchange Commission on February 27, 2024 Registration No. |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number: 001-40761 BIOTRICITY INC. (Exa |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR |
|
| February 2, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 30, 2024 BIOTRICITY INC. |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number: 001-40761 BIOTRICITY INC. (Ex |
|
| November 6, 2023 |
Exhibit 4.1 fTHIS NOTE HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. BIOTRICITY INC. CONVERTIBLE PREFERRED NOTE Prin |
|
| November 6, 2023 |
Form of Subscription Agreement Exhibit 10.1 SUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT (this “Agreement”) is dated as of the date contained in the signature page hereto (the “Closing Date”), by and between BIOTRICITY INC., a Nevada corporation (the “Company”), and the subscriber identified on the signature page hereto (the “Subscriber”). RECITALS WHEREAS, the Company seeks to sell Convertible Preferred Notes in the form |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 31, 2023 BIOTRICITY INC. |
|
| September 20, 2023 |
Exhibit 10.2 VOTING AGREEMENT VOTING AGREEMENT, dated as of September 19, 2023 (this “Agreement”), by and among Biotricity Inc., a Nevada corporation, (the “Company”), (the “Investor”), and the stockholders whose names appear on the signature pages hereto (each, a “Stockholder” and collectively, the “Stockholders”). WHEREAS, the Company and the Investor have entered into a Securities Purchase Agre |
|
| September 20, 2023 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of September 19, 2023, is by and among Biotricity Inc., a Nevada corporation with offices located at 203 Redwood Parkway, Suite 600, Redwood City, CA 94065 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 19, 2023 BIOTRICITY INC. |
|
| September 20, 2023 |
Exhibit 3.1 CERTIFICATE OF DESIGNATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK OF BIOTRICITY INC. I, Waqaas Al-Siddiq, hereby certify that I am the Chief Executive Officer of Biotricity Inc. (the “Company”), a corporation organized and existing under the Nevada Revised Statutes (the “NRS”), and further do hereby certify: That pursuant to the authority expressly conferred upon the Board of Directo |
|
| September 19, 2023 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-255544 PROSPECTUS SUPPLEMENT (To Prospectus dated May 4, 2021) Biotricity Inc. 220 Shares of Series B Convertible Preferred Stock Up to 1,704,593 Shares of Common Stock Underlying the Series B Convertible Preferred Stock Biotricity Inc. is offering 220 shares of our Series B Convertible Preferred Stock, par value $0.001, or the Series B Preferr |
|
| August 17, 2023 |
Exhibit 99.1 Biotricity Reports Strong Growth for its First Quarter Fiscal Year 2024 and Provides Financial Results and Business Updates REDWOOD CITY, CA / ACCESSWIRE / August 15, 2023 / Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 15, 2023 BIOTRICITY INC. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number: 000-40761 BIOTRICITY INC. (Exact n |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 1, 2023 BIOTRICITY INC. |
|
| July 21, 2023 |
Biotricity, Inc. Up to $8,277,159 Common Stock PROSPECTUS SUPPLEMENT (To Prospectus dated April 27, 2021) Filed Pursuant to Rule 424(b)(3) Registration No. |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 18, 2023 BIOTRICITY INC. |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 29, 2023 BIOTRICITY INC. |
|
| July 5, 2023 |
Biotricity Announces Reverse Stock Split Exhibit 99.2 Biotricity Announces Reverse Stock Split REDWOOD CITY, CA / ACCESSWIRE / June 30, 2023 / Biotricity Holdings, Inc. (“Biotricity” or the “Company”) (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today it will effect a reverse stock split of its common stock. Biotricity expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Cap |
|
| July 5, 2023 |
Exhibit 3.1 |
|
| July 5, 2023 |
Exhibit 99.1 Biotricity Reports Business Update, Financial Results for Q4 and Full Year FY23; Company Posts Robust Revenue Growth, Overall Higher Margins, with Lower SG&A Driving Clear Path to Positive Cash Flow ● Company advancing toward positive cashflow likely by end of CY 2024 ● Accelerating product sales, and customer re-order revenue, ● FY23 revenue rose 26% YOY to $9.64 million on 5% lower |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-56074 BIOTRICITY INC. (Exact name of registrant as specified in its ch |
|
| May 18, 2023 |
Form of Convertible Promissory Note Exhibit 10.2 Exhibit B CONVERTIBLE PROMISSORY NOTE THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION |
|
| May 18, 2023 |
EX-10.3 4 ex10-3.htm Exhibit 10.3 Exhibit B WARRANT THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FRO |
|
| May 18, 2023 |
Form of Subscription Agreement Exhibit 10.1 SUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT (this “Agreement”) is dated as of the date contained in the signature page hereto (the “Closing Date”), by and between BIOTRICITY INC., a Nevada corporation (the “Company”), and the subscriber identified on the signature page hereto (the “Subscriber”). RECITALS WHEREAS, the Company seeks to sell a maximum of $10,000,000 in Convertible |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2023 BIOTRICITY INC. |
|
| May 18, 2023 |
Exhibit 10.4 VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”) is made as of the day of February, 2023, by and among (i) Biotricity, Inc., a Nevada corporation (the “Company”), (ii) the Persons listed on Schedule A (together with any subsequent investors who become parties hereto as “Investors” pursuant to Subsection 4.1(b), the “Investors”), and (iii) the Persons listed on Schedule B here |
|
| April 3, 2023 |
Exhibit 10.1 BIOTRICITY INC. 2023 INCENTIVE PLAN SECTION 1. PURPOSE The purpose of the Biotricity Inc. 2023 Incentive Plan is to attract, retain and motivate employees, officers, directors, consultants, agents, advisors and independent contractors of the Company and its Related Companies by providing them the opportunity to acquire a proprietary interest in the Company and to align their interests |
|
| April 3, 2023 |
Exhibit 10.2 APPROVAL OF THE BIOTRICITY, INC. EMPLOYEE STOCK PURCHASE PLAN OVERVIEW On February 24, 2023, the Company’s Board of Directors approved the Company’s Employee Stock Purchase Plan (the “ESPP”) subject to approval of the ESPP by the Company’s shareholders. If the ESPP is approved, the Company will be authorized to offer eligible employees of the Company and its designated subsidiaries th |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 31, 2023 BIOTRICITY, INC. |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number: 000-56074 BIOTRICITY INC. (Exa |
|
| February 14, 2023 |
4.1 Form of Convertible Preferred Note Exhibit 4.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. BIOTRICITY INC. CONVERTIBLE PREFERRED NOTE Princ |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 23, 2023 BIOTRICITY, INC. |
|
| January 20, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 20, 2023 BIOTRICITY INC. |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 14, 2022 BIOTRICITY INC. |
|
| November 18, 2022 |
Biotricity Reports Financial Results for Fiscal 2023 Second Quarter Exhibit 99.1 Biotricity Reports Financial Results for Fiscal 2023 Second Quarter Revenue totaled $2.4 million, up 14% sequentially quarter-over-quarter REDWOOD CITY, CA / ACCESSWIRE / November 14, 2022 / Biotricity Inc. (NASDAQ:BTCY) (?Biotricity? or the ?Company?), a medical diagnostic and consumer healthcare technology company, today announced its financial results and provided a business update |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number: 000-56074 BIOTRICITY INC. (Ex |
|
| August 17, 2022 |
Biotricity Reports Financial Results for Fiscal 2023 First Quarter Exhibit 99.1 Biotricity Reports Financial Results for Fiscal 2023 First Quarter REDWOOD CITY, CA / ACCESSWIRE / August 15, 2022 / Biotricity Inc. (NASDAQ:BTCY) (?Biotricity? or the ?Company?), a medical diagnostic and consumer healthcare technology company, today announced its financial results for its fiscal 2023 first quarter ended June 30, 2022. Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity |
|
| August 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 15, 2022 BIOTRICITY INC. |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number: 000-56074 BIOTRICITY INC. (Exact n |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 5, 2022 BIOTRICITY INC. |
|
| July 18, 2022 |
Biotricity Reports Financial Results for Fiscal 2022 Fourth Quarter and Full Year Exhibit 99.1 Biotricity Reports Financial Results for Fiscal 2022 Fourth Quarter and Full Year Thursday, July 14th at 8:00 AM Company Reports Record Revenue and Improved Margins REDWOOD CITY, CA / ACCESSWIRE / July 14, 2022 / Biotricity Inc. (NASDAQ:BTCY) (?Biotricity? or the ?Company?), a medical diagnostic and consumer healthcare technology company, today announced its financial results for its |
|
| July 18, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 14, 2022 BIOTRICITY INC. |
|
| July 14, 2022 |
Compensation Committee Charter Exhibit 99.2 CHARTER OF THE COMPENSATION COMMITTEE OF BIOTRICITY INC. Membership The Compensation Committee (the ?Committee?) of the board of directors (the ?Board?) of Biotricity Inc. (the ?Company?) shall consist of two or more directors. Each member of the Committee shall be independent in accordance with the rules of the NASDAQ Stock Market LLC (?NASDAQ?) and the Company?s independence guideli |
|
| July 14, 2022 |
Exhibit 99.1 CHARTER OF THE AUDIT COMMITTEE OF BIOTRICYT INC. Membership The Audit Committee (the ?Committee?) of the board of directors (the ?Board?) of Biotricty Inc. (the ?Company?) shall consist of three or more directors. Each member of the Committee shall be independent in accordance with the requirements of Rule 10A-3 of the Securities Exchange Act of 1934 and the rules of the NASDAQ Stock |
|
| July 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-56074 BIOTRICITY INC. (Exact name of registrant as specified in its ch |
|
| July 14, 2022 |
Nominating and Corporate Governance Committee Charter Exhibit 99.3 CHARTER OF THE NOMINATING AND CORPORATE GOVERNANCE COMMITTEE OF BIOTRICITY INC. Membership The Nominating and Corporate Governance Committee (the ?Committee?) of the board of directors (the ?Board?) of Biotricity Inc. (the ?Company?) shall consist of two or more directors. Each member of the Committee shall be independent in accordance with the rules of the NASDAQ Stock Market LLC (?N |
|
| June 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ?Transition Report on Form N-SAR For |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 2, 2022 BIOTRICITY INC. |
|
| April 27, 2022 |
PROSPECTUS 10,947,201 Shares of Common Stock BIOTRICITY INC. Filed Pursuant to Rule 424(b)(5) Registration No. 333-262288 PROSPECTUS 10,947,201 Shares of Common Stock BIOTRICITY INC. This prospectus relates to the public offering of up to 10,947,201 shares of our common stock, par value $0.001 per share (the ?Common Stock?), by the selling stockholder which is comprised of shares of Common Stock issued to the selling stockholders upon the conversion of conv |
|
| April 20, 2022 |
Biotricity Inc. 275 Shoreline Drive, Suite 150 Redwood City, CA 94065 April 21, 2022 Biotricity Inc. 275 Shoreline Drive, Suite 150 Redwood City, CA 94065 April 21, 2022 Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attention: Ms. Abby Adams Re: Biotricity Inc. Registration Statement on Form S-3 Filed April 14, 2022 File No. 333-262288 Ms. Adams: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amen |
|
| April 14, 2022 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON APRIL 14, 2022 REGISTRATION NO. |
|
| April 8, 2022 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of each class of Securities to be registered Amount to be registered(1) Proposed maximum offering price per share(2) Proposed maximum aggregate offering price Amount of registration Fee Common Stock, par value $0. |
|
| April 8, 2022 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON APRIL 8, 2022 REGISTRATION NO. |
|
| March 22, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 22, 2022 BIOTRICITY INC. |
|
| March 22, 2022 |
Biotricity, Inc. Up to $50,000,000 Common Stock PROSPECTUS SUPPLEMENT (To Prospectus dated April 27, 2021) Filed Pursuant to 424(b)(3) File No. |
|
| March 22, 2022 |
Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT March 22, 2022 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Biotricity Inc., a corporation organized under the laws of Nevada (the ?Company?), confirms its agreement (this ?Agreement?) with H.C. Wainwright & Co., LLC (the ?Manager?) as follows: 1. Definitions. The terms that follow, when used in this Agreeme |
|
| February 16, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 14, 2022 BIOTRICITY INC. |
|
| February 16, 2022 |
Biotricity Releases Fiscal 2022 Third Quarter Financial Results Exhibit 99.1 Biotricity Releases Fiscal 2022 Third Quarter Financial Results Management to host investor call on Tuesday February 15th at 4:15 pm ET ? 93% YOY Revenue Gains to $1.93 Million ? Revenue Outpaces SG&A Increase by 2.2x ? Cash Position of $16.8 Million at Quarter End Is Highest Ever ? Continues to Anticipate Full-Year Triple-Digit Revenue Growth REDWOOD CITY, CA / ACCESSWIRE / February |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number: 000-56074 BIOTRICITY INC. (Exa |
|
| January 21, 2022 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JANUARY 21, 2022 REGISTRATION NO. |
|
| December 28, 2021 |
Exhibit 10.4 INTELLECTUAL PROPERTY SECURITY AGREEMENT This INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of December 21, 2021 (as may be amended, restated, amended and restated, waived, supplemented, or otherwise modified from time to time, this ?Agreement?), made by BIOTRICITY INC., a Nevada corporation (?Grantor?), in favor of SWK FUNDING LLC, a Delaware limited liability company, as agent |
|
| December 28, 2021 |
Exhibit 10.3 GUARANTEE AND COLLATERAL AGREEMENT dated as of December 21, 2021 among biotricity inc., and each other Person that becomes a party hereto as a grantor, each as a Grantor, and SWK FUNDING LLC, as Agent GUARANTEE AND COLLATERAL AGREEMENT Guarantee and Collateral Agreement, dated as of December 21, 2021 (as may be amended, restated, amended and restated, waived, supplemented, or otherwis |
|
| December 28, 2021 |
Exhibit 10.2 WARRANT THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJ |
|
| December 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 21, 2021 BIOTRICITY INC. |
|
| December 28, 2021 |
Exhibit 10.1 Execution Version CREDIT AGREEMENT among BIOTRICITY INC., as Borrower, SWK FUNDING LLC, as Agent, Sole Lead Arranger and Sole Bookrunner, and the financial institutions party hereto from time to time as Lenders Dated as of December 21, 2021 Table of Contents Page Section 1 Definitions; Interpretation. 1 1.1 Definitions 1 1.2 Interpretation 16 Section 2 Credit Facility. 17 2.1 Term Loa |
|
| December 8, 2021 |
Exhibit 99.1 Leader in Remote Cardiac Health Monitoring Solutions, Biotricity CEO Issues 2021 Shareholder Letter Company is ?well-positioned and fully confident that 2022 will prove to be our historically pivotal breakout year.? Letter highlights milestones, products roadmap, growth strategy and 2022 goals REDWOOD CITY, CA / December XX, 2021 /Biotricity, Inc. (NASDAQ: BTCY) (?Biotricity? or the ? |
|
| December 8, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 7, 2021 BIOTRICITY INC. |
|
| December 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 6, 2021 BIOTRICITY INC. |
|
| December 7, 2021 |
Exhibit 99.1 |
|
| November 5, 2021 |
Biotricity Releases Fiscal 2022 Second Quarter Financial Results Exhibit 99.1 Biotricity Releases Fiscal 2022 Second Quarter Financial Results ? Company reports tenth consecutive quarter of triple-digit year-over-year revenue growth ? Strongest balance sheet since inception REDWOOD CITY, CA / ACCESSWIRE / November 4, 2021 /Biotricity Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced financial results for its 20 |
|
| November 5, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 4, 2021 BIOTRICITY INC. |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number: 000-56074 BIOTRICITY INC. (Ex |
|
| September 13, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 13, 2021 BIOTRICITY, INC. |
|
| September 13, 2021 |
Exhibit 99.1 Biotricity Announces Closing of Exercise of Underwriter?s Option to Purchase Additional Common Stock Underwritten Public Offering of Common Stock Resulted in Total Gross Proceeds of $16 Million REDWOOD CITY, CA / ACCESSWIRE / September 13, 2021 / Biotricity, Inc. (NASDAQ: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that the underwriter of it |
|
| September 10, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): September 8, 2021 BIOTRICITY INC. |
|
| September 10, 2021 |
Company’s Momentum Continuing with Sales Growth, Recent Nasdaq listing and Successful Equity Raise Exhibit 99.1 Company?s Momentum Continuing with Sales Growth, Recent Nasdaq listing and Successful Equity Raise REDWOOD CITY, CA / ACCESSWIRE / September 8, 2021 / Biotricity, Inc. (NASDAQ:BTCY) (?Biotricity? or the ?Company?), a medical diagnostic and consumer healthcare technology company, today reported its CEO Waqaas Al-Siddiq is scheduled to present at the H.C. Wainwright 23rd Annual Global I |
|
| August 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 26, 2021 BIOTRICITY, INC. |
|
| August 31, 2021 |
Underwriting Agreement, dated as of August 25, 2021 EX-1.1 2 ex1-1.htm Exhibit 1.1 5,000,000 SHARES of Common Stock BIOTRICITY INC. UNDERWRITING AGREEMENT August 26, 2021 H.C. Wainwright & Co., LLC 430 Park Avenue, 3rd Floor New York, NY 10022 As the Representative of the Several underwriters, if any, named in Schedule I hereto Ladies and Gentlemen: The undersigned, Biotricity Inc., a company incorporated under the laws of Nevada (collectively with |
|
| August 31, 2021 |
Exhibit 99.1 Biotricity Prices $15 Million Underwritten Public Offering of Common Stock and Listing on the Nasdaq Capital Market REDWOOD CITY, CA / ACCESSWIRE / August 26, 2021 / Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced the pricing of an underwritten public offering of 5,000,000 shares of common stock of the Company, at a price |
|
| August 31, 2021 |
Biotricity Closes $15 Million Underwritten Public Offering Completes Nasdaq Uplist Exhibit 99.2 Biotricity Closes $15 Million Underwritten Public Offering Completes Nasdaq Uplist REDWOOD CITY, CA / ACCESSWIRE / August 30, 2021 / Biotricity, Inc. (NASDAQ: BTCY), a medical diagnostic and consumer healthcare technology company, today announced the closing of an underwritten public offering of 5,000,000 shares of common stock of the Company for total gross proceeds to the Company of |
|
| August 31, 2021 |
Exhibit 4.1 UNDERWRITER COMMON STOCK PURCHASE WARRANT BIOTRICITY, INC. Warrant Shares: Initial Exercise Date: August 30, 2021 THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| August 30, 2021 |
PROSPECTUS SUPPLEMENT (To Prospectus dated April 27, 2021) Filed Pursuant to 424(b)(5) File No. |
|
| August 25, 2021 |
SUBJECT TO COMPLETION, DATED AUGUST 25, 2021 The information in this prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are not soliciting offers to buy these securities in any state where the |
|
| August 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOTRICITY INC. |
|
| August 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number: 000-56074 BIOTRICITY INC. (Exact n |
|
| August 17, 2021 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 000-56074 NOTIFICATION OF LATE FILING CUSIP NUMBER 09074H 104 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period End |
|
| August 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Amendment No. 1) (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number: 000-56074 BIOT |
|
| August 17, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 16, 2021 BIOTRICITY INC. |
|
| August 17, 2021 |
Biotricity Reports 290% Revenue Growth Year Over Year in Record First Quarter Exhibit 99.1 Biotricity Reports 290% Revenue Growth Year Over Year in Record First Quarter REDWOOD CITY, CA / ACCESSWIRE / August 16, 2021 /Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, is pleased to provide financial results for its fiscal 2022 first quarter, which ended June 30, 2021. Full financial results will be posted on EDGAR later today. Bi |
|
| July 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 07, 2021 BIOTRICITY INC. |
|
| July 8, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Biotricity’s 2021 Fiscal Fourth Quarter Growth Trend Continues into Fiscal 2022 Fiscal Q1-22 to be the 9th quarter of growth and biggest quarter to date REDWOOD CITY, CA / ACCESSWIRE / July 7, 2021 /Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced preliminary revenue results guidance for its 2022 fisca |
|
| June 22, 2021 |
Compensation Committee Charter Exhibit 99.2 CHARTER OF THE COMPENSATION COMMITTEE OF BIOTRICITY INC. Membership The Compensation Committee (the ?Committee?) of the board of directors (the ?Board?) of Biotricity Inc. (the ?Company?) shall consist of two or more directors. Each member of the Committee shall be independent in accordance with the rules of the NASDAQ Stock Market LLC (?NASDAQ?) and the Company?s independence guideli |
|
| June 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: March 31, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-56074 BIOTRICITY INC. (Exact name of registrant as specified in it |
|
| June 22, 2021 |
Exhibit 99.1 CHARTER OF THE AUDIT COMMITTEE OF BIOTRICYT INC. Membership The Audit Committee (the ?Committee?) of the board of directors (the ?Board?) of Biotricty Inc. (the ?Company?) shall consist of three or more directors. Each member of the Committee shall be independent in accordance with the requirements of Rule 10A-3 of the Securities Exchange Act of 1934 and the rules of the NASDAQ Stock |
|
| June 22, 2021 |
Nominating and Corporate Governance Committee Charter Exhibit 99.3 CHARTER OF THE NOMINATING AND CORPORATE GOVERNANCE COMMITTEE OF BIOTRICITY INC. Membership The Nominating and Corporate Governance Committee (the ?Committee?) of the board of directors (the ?Board?) of Biotricity Inc. (the ?Company?) shall consist of two or more directors. Each member of the Committee shall be independent in accordance with the rules of the NASDAQ Stock Market LLC (?N |
|
| June 17, 2021 |
Biotricity Reports Record Quarterly and Annual Revenue for Fiscal 2021 Exhibit 99.1 Biotricity Reports Record Quarterly and Annual Revenue for Fiscal 2021 REDWOOD CITY, CA / ACCESSWIRE / June 15, 2021 / Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, is pleased to provide unaudited, preliminary financial results for its fiscal 2021 fourth quarter and fiscal year, which ended March 31, 2021. Full financial results will b |
|
| June 17, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 15, 2021 BIOTRICITY INC. |
|
| April 30, 2021 |
April 30, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 11, 2020 BIOTRICITY INC. |
|
| April 27, 2021 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON APRIL 27, 2021 REGISTRATION NO. |
|
| April 15, 2021 |
Biotricity to Report Record Revenue Results for Fiscal 2021 EX-99.1 2 ex99-1.htm Exhibit 99.1 Biotricity to Report Record Revenue Results for Fiscal 2021 Wed, April 14, 2021, 8:00 AM·6 min read Unaudited Financial Results Include Revenue Growth of 133% REDWOOD CITY, CA / ACCESSWIRE / April 14, 2021 / Biotricity, Inc. (OTCQB:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, is pleased to announce another |
|
| April 15, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 14, 2021 BIOTRICITY INC. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number: 000-56074 BIOTRICITY INC. |
|
| February 12, 2021 |
Biotricity to Report Third Quarter Fiscal 2021 Financial Results on February 11, 2021 EX-99.2 3 ex99-2.htm Exhibit 99.2 Biotricity to Report Third Quarter Fiscal 2021 Financial Results on February 11, 2021 Biotricity Mon, February 8, 2021, 8:00 AM·4 min read REDWOOD CITY, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) - Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will discuss the highlights of its financial results |
|
| February 12, 2021 |
Biotricity Reports Record Revenue; Tops $1.0 Million in Quarterly Revenue for the First Time EX-99.1 2 ex99-1.htm Exhibit 99.1 Biotricity Reports Record Revenue; Tops $1.0 Million in Quarterly Revenue for the First Time Thu, February 11, 2021, 4:05 PM·6 min read REDWOOD CITY, CA / ACCESSWIRE / February 11, 2021 /Biotricity, Inc. (OTCQB:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, is pleased to provide unaudited, preliminary financ |
|
| February 12, 2021 |
Other Events, Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 8, 2021 BIOTRICITY INC. |
|
| January 22, 2021 |
Form of Warrant (incorporated by reference to 8-K filed August 6, 2020) EX-10.3 4 ex10-3.htm Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT T |
|
| January 22, 2021 |
EX-10.2 3 ex10-2.htm Exhibit 10.2 CONVERTIBLE PROMISSORY NOTE THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN |
|
| January 22, 2021 |
Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of , 2020 by and among (i) Biotricity Inc., a Nevada corporation (the “Company”), and the Purchasers named on Schedule I (each, a “Purchaser” and, together, the “Purchasers”). RECITALS: WHEREAS, the Purchasers have agreed to purchase from the Company, and the Company has agr |
|
| January 22, 2021 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this “Agreement”) is made as of by and among BIOTRICITY, INC., a Nevada corporation (the “Company”), and the subscribers identified on the signature pages hereto (each, a “Subscriber” and collectively, the “Subscribers”). RECITALS WHEREAS, the Company seeks to sell a maximum of $10,000,000 (or such higher amount |
|
| January 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): January 15, 2021 BIOTRICITY INC. |
|
| December 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): December 24, 2020 BIOTRICITY INC. |
|
| November 20, 2020 |
Biotricity Reports Results for the Quarter Ended September 30, 2020 Exhibit 99.1 Biotricity Reports Results for the Quarter Ended September 30, 2020 biotricity Tue, November 17, 2020, 6:30 PM GMT+5:30·5 min read ● Revenues grow 64.8% over the immediately preceding quarter and a 115.3% increase over the corresponding period of the prior year ● Loss per share of 8.5 cents in line with levels of immediately preceding quarter REDWOOD CITY, Calif., Nov. 17, 2020 (GLOBE |
|
| November 20, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 17, 2020 BIOTRICITY INC. |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number: 000-56074 BIOTRICITY INC. |
|
| August 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number: 000-56074 BIOTRICITY INC. (Exa |
|
| August 14, 2020 |
4.1 Note with U.S. Small Business Administration Exhibit 4.1 |
|
| August 13, 2020 |
Definitive Agreement of Understanding Exhibit 99.1 |
|
| August 13, 2020 |
Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): August 11, 2020 BIOTRICITY INC. |
|
| August 6, 2020 |
Exhibit 10.2 CONVERTIBLE PROMISSORY NOTE THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE |
|
| August 6, 2020 |
Exhibit 10.1 SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Agreement”) is made as of , 2020 by and among BIOTRICITY, INC., a Nevada corporation (the “Company”), and the subscribers identified on the signature pages hereto (each, a “Subscriber” and collectively, the “Subscribers”). Recitals Whereas, the Company seeks to sell a maximum of $10,000,000 (or such higher amount as the Company |
|
| August 6, 2020 |
Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of , 2020 by and among (i) Biotricity Inc., a Nevada corporation (the “Company”), and the Purchasers named on Schedule I (each, a “Purchaser” and, together, the “Purchasers”). RECITALS: WHEREAS, the Purchasers have agreed to purchase from the Company, and the Company has agr |
|
| August 6, 2020 |
Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act Of 1934 Date of report (Date of earliest event reported): July 31, 2020 BIOTRICITY INC. |
|
| July 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: March 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-56074 BIOTRICITY INC. (Exact name of registrant as specified in it |
|
| July 15, 2020 |
Exhibit 4.12 |
|
| July 13, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 8, 2020 BIOTRICITY INC. |
|
| July 13, 2020 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Biotricity Shows Continued Growth through its Preliminary Year-End Guidance and Provides Calendar Second Quarter Update REDWOOD CITY, Calif., July 08, 2020 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today provided guidance on its financial results for the year ended March 31, 2020, announcing |
|
| June 30, 2020 |
BTCY / Biotricity Inc. / Al-Siddiq Waqaas Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 BIOTRICITY INC. (Name of Issuer) Common Stock, $.001 Par Value PER SHARE (Title of Class of Securities) 09074H 104 (CUSIP Number) Waqaas Al-Siddiq c/o Biotricty Inc. 275 Redwood City, California 94065 (650) 832-1626 (Name, Address and Telephone Number of Person Authorized |
|
| June 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 26, 2020 BIOTRICITY INC. |
|
| June 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 11, 2020 (April 23, 2020) BIOTRICITY INC. |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 5, 2020 BIOTRICITY INC. |
|
| April 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 7, 2020 BIOTRICITY INC. |
|
| April 13, 2020 |
Exhibit 99.1 BIOTRICITY, INC. STATEMENT OF COMPANY POLICY REGARDING CONFIDENTIALITY AND SECURITIES TRADES BY COMPANY PERSONNEL 1. CONFIDENTIALITY OF INSIDE INFORMATION 1.1 Directors, officers, employees and consultants (“Company Personnel”) of Biotricity, Inc. (the “Company”), who come into possession of material non-public information concerning the Company must safeguard the information and not |
|
| April 13, 2020 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of the day of April 2020 (the “Effective Date”), by and between BIOTRICITY INC., a Nevada corporation (the “Employer”), and WAQAAS AL-SIDDIQ (the “Executive”). RECITALS WHEREAS the Employer and the Executive have agreed to enter into this Agreement to formalize in writing the terms and con |
|
| February 20, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 18, 2020 BIOTRICITY INC. (Exact name of registrant as specified in its charter) Nevada 000-56074 47-2548273 (State or Other Jurisdiction of Incorporation or O |
|
| February 20, 2020 |
Biotricity Posts Calendar Q4 Results that Show Continued Growth Exhibit 99.1 Biotricity Posts Calendar Q4 Results that Show Continued Growth REDWOOD CITY, CA – February 18, 2020 – Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced calendar fourth quarter financial results for the three months which ended December 31, 2019. FOURTH QUARTER HIGHLIGHTS ● Revenues for the three months which ended December |
|
| February 14, 2020 |
BTCY / Biotricity Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number: 000-56074 BIOTRICITY INC. |
|
| January 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 7, 2020 BIOTRICITY INC. |
|
| January 13, 2020 |
Exhibit 10.1 EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) dated this day of , 20 by and among Biotricity, Inc., a Nevada corporation (the “Company”) and , a (the “Holder”). WHEREAS, the Holder is the holder of a promissory note of the Company, dated on or about , in the original principal amount of $ (the “Note”); WHEREAS, the Company and the Holder desire to have the Holder excha |
|
| December 23, 2019 |
EX-3.1 2 ex3-1.htm |
|
| December 23, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 20, 2019 BIOTRICITY INC. |
|
| December 20, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 19, 2019 BIOTRICITY INC. |
|
| December 20, 2019 |
Exhibit 3.1 CERTIFICATE OF DESIGNATION OF RIGHTS, POWERS, PREFERENCES, PRIVILEGES AND RESTRICTIONS of SERIES A CONVERTIBLE PREFERRED STOCK OF BIOTRICITY INC. I, Waqaas Al-Siddiq, hereby certify that I am the Chief Executive Officer of Biotricity Inc. (the “Company”), a corporation organized and existing under the Nevada Revised Statutes (the “NRS”), and further do hereby certify: That, pursuant to |
|
| December 20, 2019 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December , 2019, by and among Biotricity Inc., a Nevada corporation (the “Company”), and the purchasers identified on the signature pages hereto (including any successors and assigns, the “Purchaser(s)”). WHEREAS, the Company has authorized a new series of preferred stock designated as S |
|
| November 14, 2019 |
MTSU / MetaSolutions, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number: 000-56074 BIOTRICITY INC. |
|
| October 8, 2019 |
8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 3, 2019 BIOTRICITY INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-56074 47-2548273 (State or Other Jurisdiction of Incorporation or Org |
|
| August 29, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 26, 2019 BIOTRICITY INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-56074 47-2548273 (State or Other Jurisdiction of Incorporation or Org |
|
| August 29, 2019 |
Biotricity Reports Fiscal Q1 Results Showing A Strong Growth Trajectory Biotricity Reports Fiscal Q1 Results Showing A Strong Growth Trajectory REDWOOD CITY, Calif. |
|
| August 15, 2019 |
MTSU / MetaSolutions, Inc. NT 10-Q - - NT 10-Q 1 formnt10-q.htm UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 000-65074 NOTIFICATION OF LATE FILING CUSIP NUMBER 09074H 104 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] |
|
| August 15, 2019 |
MTSU / MetaSolutions, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the period from to Commission file number: 333-201719 BIOTRICITY INC. ( |
|
| August 15, 2019 |
EX-10.1 2 ex10-1.htm SUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT (this “Agreement”) isdated as of the date contained in the signature page hereto (the “Closing Date”), by and between BIOTRICITY INC., a Nevada corporation (the “Company”), and the subscriber identified on the signature page hereto (the “Subscriber”). RECITALS WHEREAS, the Company seeks to sell Convertible Promissory Notes in |
|
| July 16, 2019 |
Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOTRICITY INC. |
|
| July 16, 2019 |
MTSU / MetaSolutions, Inc. 10-K - Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: March 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 333-201719 BIOTRICITY INC. (Exact name of registrant as specified in i |
|
| July 12, 2019 |
8-K 1 biotricity8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 9, 2019 BIOTRICITY INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 333-201719 47-2548273 (State or Other Jurisdiction of Incorpor |
|
| July 12, 2019 |
Converted by EDGARwiz THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. |
|
| July 12, 2019 |
Converted by EDGARwiz SUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT (this “Agreement”) is dated as of the date contained in the signature page hereto (the “Closing Date”), by and between BIOTRICITY INC. |
|
| July 1, 2019 |
MTSU / MetaSolutions, Inc. NT 10-K - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 333-201719 (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ |
|
| May 24, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 20, 2019 BIOTRICITY INC. |
|
| February 19, 2019 |
MTSU / MetaSolutions, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended December 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the period from to Commission file number: 333-201719 BIOTRICITY IN |
|
| February 13, 2019 |
MTSU / MetaSolutions, Inc. NT 10-Q Converted by EDGARwiz SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-201719 NOTIFICATION OF LATE FILING ¨ Form 10-K ¨ Form 11-K ¨ Form 20-F ý Form 10-Q ¨ Form N-SAR For Period Ended: December 31, 2018 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F ¨ Transition Report on Form N-SAR For the Transit |
|
| January 17, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 11, 2019 BIOTRICITY INC. |
|
| January 17, 2019 |
Biotricity provides end of year shareholder update Converted by EDGARwiz Biotricity provides end of year shareholder update Company outlines future roadmap JANUARY 11, 2019 | BY BIOTRICITY REDWOOD CITY, Calif. |
|
| January 15, 2019 |
Converted by EDGARwiz THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. |
|
| January 15, 2019 |
8-K 1 biotricity8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 7, 2019 BIOTRICITY INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 333-201719 47-2548273 (State or Other Jurisdiction of Incor |
|
| January 15, 2019 |
EX-10.2 3 exhibit102.htm FORM OF PURCHASE AGREEMENT PURCHASE AGREEMENT This Agreement (this “ Agreement”) is dated as of January 07, 2019, between Biotricity Inc., a Nevada corporation (the “Company”), and the purchaser identified on the signature page hereto (including its successors and permitted assigns, a “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement an |
|
| November 14, 2018 |
MTSU / MetaSolutions, Inc. FORM 10-Q (Quarterly Report) Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 8, 2018 |
Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 5, 2018 BIOTRICITY INC. |
|
| November 5, 2018 |
Results of Operations and Financial Condition Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 31, 2018 BIOTRICITY INC. |
|
| October 4, 2018 |
Biotricity Provides Fiscal 2018 Second Quarter Updates for Shareholders EX-99.1 2 exhibit991.htm PRESS RELEASE Biotricity Provides Fiscal 2018 Second Quarter Updates for Shareholders Press Release | 10/02/2018 REDWOOD CITY, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) - Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today provided operational updates for its fiscal 2018 second quarter which ended September 30, 2018. Bioflux 1 |
|
| October 4, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 02, 2018 BIOTRICITY, INC. |
|
| August 14, 2018 |
MTSU / MetaSolutions, Inc. 10-Q (Quarterly Report) Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 3, 2018 |
Entry into a Material Definitive Agreement Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 31, 2018 BIOTRICITY, INC. |
|
| July 25, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 biotricity8-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 24, 2018 BIOTRICITY, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 333-201719 47-2548273 (State or Other Jurisdiction of Incorporat |
|
| July 25, 2018 |
For Immediate Release Biotricity Completes Alpha Version of Deep Data Diagnostic Solution Biotricity is Testing its Deep Data and AI Technology, to be implemented in planned Bioflux 2. |
|
| July 13, 2018 |
MTSU / MetaSolutions, Inc. FORM 10-K (Annual Report) 10-K 1 biotricity10-k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: March 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 333-201719 BIOTRICITY INC. (Exact |
|
| June 29, 2018 |
MTSU / MetaSolutions, Inc. NT 10-K Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| June 28, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 28, 2018 BIOTRICITY, INC. |
